Product
M5049
Aliases
Enpatoran, M5049 high dose, M5049 low dose, M5049 medium dose (1 other aliases)
3 clinical trials
4 indications
Indication
Systemic Lupus ErythematosusIndication
Lupus ErythematosusIndication
DermatomyositisIndication
polymyositisClinical trial
A Phase II, Double-blind, Dose-Ranging, Parallel, Long-term Extension Study to Evaluate the Safety and Efficacy of Enpatoran in Participants With Subacute Cutaneous Lupus Erythematosus, Discoid Lupus Erythematosus and/or Systemic Lupus Erythematosus Having Completed the WILLOW (MS200569_0003) Study Treatment (WILLOW LTE)Status: Recruiting, Estimated PCD: 2025-04-15
Clinical trial
A Phase Ib, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Safety and Pharmacokinetics of Multiple Ascending Doses of M5049 Administered Orally in SLE and CLE Participants Treated With Standard of CareStatus: Completed, Estimated PCD: 2023-12-19
Clinical trial
A Phase IIa, Randomized, Parallel, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Enpatoran in Dermatomyositis and Polymyositis Participants Receiving Standard of Care (NEPTUNIA)Status: Recruiting, Estimated PCD: 2024-07-16